X

Trial Profile

An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alipogene tiparvovec (Primary) ; Ciclosporin; Mycophenolate mofetil; Prednisolone
Indications Hyperlipoproteinaemia type I
Focus Therapeutic Use
Sponsors uniQure

Most Recent Events

20 Jul 2017 Status changed from recruiting to withdrawn prior to enrolment because uniQure., has decided not to renew the Marketing Authorization of Glybera in the EU and this decision is not related to any safety, efficacy or quality issue .
13 Oct 2016 Status changed from not yet recruiting to recruiting.
03 Oct 2016 Planned initiation date changed from 1 Sep 2016 to 1 Oct 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com